QuiaPEG

Newsroom

Filter news by year:
Page:
1234
Oct 23, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or already approved drugs, so-called. biobetters. This is done on the basis of the company's own patent-protected technology platform, Uni-Qleaver®, which makes it possible to control a drug's release through a degradable chemical linker.

Sept 18, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) has received a so-called "Notice of Allowance" on the granting of patents in Canada.QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, announces that the company has received a so-called “Notice of Allowance” from the Canadian Patent Office.

July 16, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) has been granted another patent in the EU.

Apr 05, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" on granting of a patent in the United States

Mar 28, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) receives "Notice of Acceptance" on granting of a patent in Australia.

Mar 12, 2019

QuiaPEG Pharmaceuticals Holding AB (publ.) announces that a patent application within the fast-growing area of antibody drug conjugates* (ADC) has been submitted to the American patent office (USPTO). Granting of the application will mean that QuiaPEG will have patent protection up to and including 2013.

Feb 01, 2019

QuiaPEG Pharmaceuticals Holding AB (publ), "QuiaPEG", today announces that the company has decided on a directed new issue of shares and warrants to three investors.

QuiaPEG Pharmaceuticals Holding AB ("the Company"), listed on Spotlight, today announces that the Company's Board of Directors made the decision on February 1, 2019, with the support of authorization from the Annual General Meeting on June 18, 2018, to carry out a directed new issue of 2,058,824 shares and 2,058,824 warrants.

Dec 18, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that it has successfully registered the Uni-Qleaver® brand name in China.

Dec 11, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that one of the five largest global pharmaceutical companies will place an initial order for activated PEGs (reagents) based on the Uni-Qleaver® platform.

Dec 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre- clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster1 potential in the indications diabetes and overweight.

Page:
1234
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message